For the first-line treatment of CLL in combination with chlorambucil1
START WITH GAZYVA
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) include obinutuzumab (GAZYVA®) +
chlorambucil as a preferred first-line regimen for CLL patients with comorbidities, without del(17p)2,a,b
NCCN treatment suggestions for patients with del(17p) are not segmented by age or comorbidities. Obinutuzumab (GAZYVA) + chlorambucil is included as a suggested
treatment for this patient population. Suggested treatment regimens are listed in alphabetical order.
b
Obinutuzumab (GAZYVA) + chlorambucil is listed first as a suggested treatment regimen for this patient population. Treatment regimens are listed in order of preference.
Note: All recommendations are category 2A unless otherwise indicated.
a
Indication
GAZYVA® (obinutuzumab), in combination with chlorambucil, is indicated for the treatment of
patients with previously untreated chronic lymphocytic leukemia (CLL).
Boxed WARNINGS: HEPATITIS B VIRUS REACTIVATION AND PROGRESSIVE MULTIFOCAL
LEUKOENCEPHALOPATHY
• Hepatitis B Virus (HBV) reactivation, in some cases resulting in fulminant hepatitis, hepatic
failure, and death, can occur in patients receiving CD20-directed cytolytic antibodies,
including GAZYVA. Screen all patients for HBV infection before treatment initiation. Monitor
HBV positive patients during and after treatment with GAZYVA. Discontinue GAZYVA and
concomitant medications in the event of HBV reactivation
• Progressive Multifocal Leukoencephalopathy (PML) including fatal PML, can occur in patients
receiving GAZYVA
Please see the following pages for additional Important Safety Information and brief summary
of full Prescribing Information, including Boxed WARNINGS.